Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
NCT05358938Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial in cutaneous melanoma (CM), cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC) (4 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Participants Consenting to Trial at 12 months, Participants Completing Exercise at 12 months and 2 more. Started Jun 2022; status: active, not recruiting.
02
Conditions
cutaneous melanoma (CM)cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05358938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358938.